SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostics designed to provide physicians with clinically
actionable information to improve the patient outcomes, announces
that President and CEO Michael Nall
will present at the H.C. Wainwright 22nd Annual Global
Investment Conference on Monday, September
14, 2020 at 3:30 p.m. Eastern
time (12:30 p.m. Pacific
time).
The live presentation can be accessed here and will be archived
on the Investor Relations section of the Biocept website.
About Biocept
Biocept, Inc. is a molecular
diagnostics company with commercialized assays for lung, breast,
gastric, colorectal and prostate cancers, and melanoma. The Company
uses its proprietary liquid biopsy technology to provide physicians
with clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In
addition, Biocept recently added COVID-19 testing to support
efforts to fight the pandemic. For additional information, please
visit www.biocept.com.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-hc-wainwright-global-investment-virtual-conference-on-september-14-301126200.html
SOURCE Biocept, Inc.